Radionuclide ejection fraction in @entity632 XXXX .

@entity1 @entity632 @entity6470 @entity712 @entity37763 @entity1370 @entity65
Serial assessment of cardiac function by radionuclide ejection fraction (EF), using a "first-pass" technique, was performed prior to each dose in 292 @entity1 receiving @entity632 . Detailed analysis was undertaken in 98 @entity1 , consisting of all 91 @entity1 who had received greater than 200 mg/m2 and seven with risk factors (RFs) who had received between 100 and 200 mg/m2. Thirty-two @entity1 had RFs and 66 had no risk factors (NRFs). RFs were: (a) @entity65 , (b) mediastinal irradiation within 6 months of starting @entity632 treatment, and (c) total @entity632 dose greater than 550 mg/m2. The criteria for discontinuing @entity632 were EF less than 0.40 in @entity6470 @entity1 or less than 0.35 in @entity37763 @entity1 or decrease in EF of greater than or equal to 0.14 over three successive readings. In the @entity37763 group, no @entity1 met these criteria nor did any develop @entity712 . In the @entity6470 group, discontinuation was indicated in eight @entity1 : two stopped receiving @entity632 at total doses of 730 mg/m2 and 680 mg/m2, respectively, and it was discontinued in the other six at total doses ranging from 120 to 420 mg/m2. Prior to the first dose of @entity632 , all @entity1 should have a baseline EF and assessment of RFs. An EF study is required before each subsequent dose in @entity1 with RFs or with initial EF less than 0.45, but in the remaining @entity1 , serial studies are not required until there is a cumulative dose of 450 mg/m2. Use of these guidelines and our criteria for discontinuation may prevent development of @entity632 @entity1370 .
